Zafgen, Inc.

Industry · 9 registered clinical trials.

Status	Trial	Phase	Started
Completed	Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes Type 2 Diabetes Mellitus, Overweight and Obesity	Phase 2	2017-09-12
Terminated	An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus Obesity, Type 2 Diabetes	Phase 2	2014-12-01
Terminated	Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syn Prader-Willi Syndrome, Obesity	Phase 3	2014-09-01
Completed	An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury Obesity, Over-weight, Hypothalamic Injury	Phase 2	2014-04-01
Completed	An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome Obesity, Over-weight, Prader-Willi Syndrome	Phase 2	2013-06-01
Completed	An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subje Obesity	Phase 2	2012-08-01
Completed	ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity Obesity	Phase 1	2011-12-01
Completed	Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers Obesity	Phase 1	2011-06-01
Completed	Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers Obesity	Phase 1	2009-12-01